MaxCyte, Inc. (MXCT)
| Market Cap | 93.73M |
| Revenue (ttm) | 33.03M |
| Net Income (ttm) | -44.63M |
| Shares Out | 106.86M |
| EPS (ttm) | -0.42 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 378,458 |
| Open | 0.870 |
| Previous Close | 0.874 |
| Day's Range | 0.850 - 0.884 |
| 52-Week Range | 0.643 - 2.955 |
| Beta | 1.45 |
| Analysts | Buy |
| Price Target | 5.50 (+527.07%) |
| Earnings Date | May 7, 2026 |
About MXCT
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engi... [Read more]
Financial Performance
In 2025, MaxCyte's revenue was $33.03 million, a decrease of -14.50% compared to the previous year's $38.63 million. Losses were -$44.63 million, 8.71% more than in 2024.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for MXCT stock is "Buy." The 12-month stock price target is $5.5, which is an increase of 527.07% from the latest price.
News
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ROCKVILLE, Md., March 31, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, developme...
MaxCyte Earnings Call Transcript: Q4 2025
2025 saw revenue decline 15% year-over-year amid SPL program exits and inventory headwinds, but new product launches, cost restructuring, and a strong balance sheet position the company for growth. 2026 guidance anticipates $30–32 million in revenue, with a back-half weighted recovery and material contributions from SeQure Dx and SPL milestones.
MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance
Fourth quarter 2025 total revenue of $7.3 million at the top of the range of previous preliminary announcement Full year 2025 revenue of $33.0 million, at the top of the range of previous preliminary ...
MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer
ROCKVILLE, Md., March 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, developme...
MaxCyte unveils ExPERT DTx™, a 96-well electroporation platform to accelerate discovery
ROCKVILLE, Md., Feb. 24, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, developm...
MaxCyte to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026
ROCKVILLE, Md., Feb. 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, developm...
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results
ROCKVILLE, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discove...
Cellares Appoints Former MaxCyte Commercial Chief Ali Soleymannezhad as Chief Commercial Officer to Lead Global IDMO Expansion, Catalyze Next Wave of Partnerships, Prepare for IPO
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced the appointment of Ali Soleymannezhad as Chief Commercia...
MaxCyte Transcript: Stephens Annual Investment Conference
Recent restructuring and SecureDx acquisition sharpened focus on early-stage customer engagement and safety in cell and gene therapy. Despite industry rationalization, strong margins and new product launches are expected to drive growth, with a rebound anticipated in the second half of next year.
MaxCyte Earnings Call Transcript: Q3 2025
Q3 2025 revenue declined year-over-year but met expectations, with cost-saving restructuring underway and a strong SPL pipeline. SecureDX integration and new product launches are expected to drive growth in 2026, while the company maintains a robust cash position and disciplined M&A focus.
MaxCyte Announces Planned CFO Transition in 2026
ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, develop...
MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance
ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, developm...
MaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance
MaxCyte will now host its earnings conference call on November 12, 2025 Management will present at the Stifel Healthcare Conference on November 11, 2025 and Stephens Investment Conference on November ...
MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025
ROCKVILLE, Md., Oct. 08, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, developm...
MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors
MaxCyte's Flow Electroporation® Technology will support efficient gene delivery to advance Moonlight Bio's engineered T cell therapies MaxCyte's Flow Electroporation® Technology will support efficient...
MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability
ROCKVILLE, Md., Sept. 22, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, develo...
MaxCyte Earnings Call Transcript: Q2 2025
Q2 2025 revenue declined 18% year-over-year, prompting a reduction in 2025 core revenue guidance due to customer program rationalizations and capital equipment hesitancy. Despite headwinds, instrument sales grew 22% and new SPLs were signed, with growth expected to resume in 2026.
MaxCyte Signs Platform License Agreement with Adicet Bio
MaxCyte's Flow Electroporation® technology and ExPERT™ platform to support development of Adicet's gamma delta T cell therapy gene edited programs
MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline
MaxCyte's Flow Electroporation® Technology will support non-viral gene editing in the manufacture of Anocca's TCR-T cell therapies MaxCyte's Flow Electroporation® Technology will support non-viral gen...
MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025
ROCKVILLE, Md., July 09, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, developm...
PHC Announces Exclusive Distribution of MaxCyte® ExPERT™ Platform in Japan
TOKYO--(BUSINESS WIRE)--The Biomedical Division of PHC Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Nobuaki Nakamura; hereafter referred to as "PHCbi"), a subsidiary of PHC Holdings Corpor...
MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies
MaxCyte and Ori Biotech successfully integrate their ExPERT™ and IRO® platforms to improve the yield of gene-edited T cells and shorten manufacturing timelines MaxCyte and Ori Biotech successfully int...
MaxCyte Earnings Call Transcript: Q1 2025
Q1 2025 revenue was $10.4M, down 8% year-over-year, with core revenue flat and SPL revenue at $2.1M. Guidance for 2025 is reaffirmed, integration of SecureDX is progressing well, and the company remains well-capitalized with $174.7M in cash and no debt.
MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance
ROCKVILLE, MD, May 7, 2025 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and co...
MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025
ROCKVILLE, Md., April 10, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discove...